ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK plus non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)

被引：2

作者：

Solomon, B. J. ^{[1
]}

Wu, Y-L. ^{[2
]}

Dziadziuszko, R. ^{[3
,4
]}

Barlesi, F. ^{[5
,6
]}

Nishio, M. ^{[7
]}

Ahn, J. S. ^{[8
]}

Horinouchi, H. ^{[9
]}

Hochmair, M. J. ^{[10
]}

de Marinis, F. ^{[11
]}

Migliorino, M. R. ^{[12
]}

Kurochkin, A. ^{[13
]}

Harputluoglu, H. ^{[14
]}

Planchard, D. ^{[5
,6
]}

Korphaisarn, K. ^{[15
]}

Han, J-Y. ^{[16
]}

Lohmann, T. ^{[17
]}

Gavaldon, A. Cardona ^{[18
]}

Archer, V. R. ^{[19
]}

Nowicka, M. ^{[20
]}

Noe, J. ^{[21
]}

机构：

[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[2] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Acad Med Sci, Oncol Dept,Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China

[3] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland

[4] Med Univ Gdansk, Early Phase Clin Trials Ctr, Gdansk, Poland

[5] Univ Paris Saclay, Dept Med Oncol, Villejuif, France

[6] Gustave Roussy, Villejuif, France

[7] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Med Oncol, Tokyo, Japan

[8] Samsung Med Ctr, Dept Hematol & Oncol, Seoul, South Korea

[9] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan

[10] Karl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Dept Resp & Crit Care Med, Vienna, Austria

[11] European Inst Oncol IRCCS, Thorac Oncol Div, Milan, Italy

[12] San Camillo Forlanini Hosp, Pneumooncol Unit, Rome, Italy

[13] RCI Sumy Reg Clin Oncol Dispensary, Oncothorac Surg Dept, Sumy Region, Kharkiv Governo, Ukraine

[14] Inonu Univ, Dept Med Oncol, Med Fac, Turgut Ozal Med Ctr, Malatya, Turkiye

[15] Mahidol Univ, Dept Med, Fac Med, Siriraj Hosp, Bangkok, Thailand

[16] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea

[17] F Hoffmann La Roche Ltd, PD Oncol, Basel, Switzerland

[18] F Hoffmann La Roche Ltd, Data & Stat Sci, Basel, Switzerland

[19] Roche Prod Ltd, PDC, Welwyn Garden City, Herts, England

[20] F Hoffmann La Roche Ltd, Computat Sci, Basel, Switzerland

[21] F Hoffmann La Roche Ltd, Translat Med, Basel, Switzerland

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1265

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1206MO

引用

页码：S775 / S775

页数：1

共 50 条

[1] ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK plus NonSmall Cell Lung Cancer (NSCLC)
Horinouchi, H.
Solomon, B. J.
Wu, Y. L.
Barlesi, F.
Nishio, M.
Ahn, J. S.
Lee, D. H.
Lee, J. S.
Zhong, W.
Hochmair, M.
Bondarenko, I.
Planchard, D.
Rittmeyer, A.
Ding, B.
Ruf, T.
Adler, L.
Scalori, A.
Dziadziuszko, R.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S39 - S39
[2] Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK plus non-small cell lung cancer (NSCLC): Data from ALINA
Nishio, Makoto
Wu, Yi-Long
Barlesi, Fabrice
Ahn, Jin Seok
Lee, Dae Ho
Lee, Jong-Seok
Zhong, Wenzhao
Horinouchi, Hidehito
Hochmair, Maximilian
Tanaka, Hiroshi
Glogowski, Maciej
Rittmeyer, Achim
Fidler, Mary J.
Wrona, Anna
Mamolo, Carla
Cardona, Andres
Ruf, Thorsten
Smoljanovic, Vlatka
Solomon, Benjamin J.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)
Solomon, B. J.
Ahn, J. S.
Dziadziuszko, R.
Barlesi, F.
Nishio, M.
Lee, D. H.
Lee, J. S.
Zhong, W. Z.
Horinouchi, H.
Mao, W.
Hochmair, M. J.
De Marinis, F.
Migliorino, M. R.
Bondarenko, I.
Lohmann, T. O.
Xu, T.
Gavaldon, A. Cardona
Bordogna, W.
Ruf, T.
Wu, Y. L.
ANNALS OF ONCOLOGY, 2023, 34 : S1295 - S1296
[4] ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)
Shah, Rajiv
Solomon, Benjamin J.
Ahn, Jin Seok
Dziadziuszko, Rafal
Barlesi, Fabrice
Nishio, Makoto
Lee, Dae Ho
Lee, Jong-Seok
Zhong, Wenzhao
Horinouchi, Hidehito
Mao, Weimin
Hochmair, Maximilian
de Marinis, Filippo
Migliorino, Maria Rita
Bondarenko, Igor
Lohmann, Tania Ochi
Xu, Tingting
Cardona, Andres
Bordogna, Walter
Ruf, Thorsten
Wu, Yi-Long
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 243 - 244
[5] Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy (CT) in patients (pts) from Asia with resected, early-stage ALK plus non-small cell lung cancer (NSCLC): A sub analysis of ALINA
Ahn, J. S.
Wu, Y-L.
Dziadziuszko, R.
Barlesi, F.
Nishio, M.
Lee, D. H.
Lee, J-S.
Zhong, W-Z.
Horinouchi, H.
Mao, W.
Lu, S.
Wang, Q.
Yang, C-T.
Korphaisarn, K.
Xu, T.
Bu, L.
Scalori, A.
Petric, P.
Redhead, K.
Solomon, B.
ANNALS OF ONCOLOGY, 2023, 34 : S1646 - S1647
[6] COST OF IMPLEMENTING ALECTINIB AS AN ADJUVANT TREATMENT FOR ALK plus NON-SMALL CELL LUNG CANCER IN DENMARK (C-ALINA)
Beck, C.
Fanoe, A.
Hillring, P.
Urbanskac, E. M.
Meldgaard, P.
VALUE IN HEALTH, 2024, 27 (12) : S130 - S130
[7] ALUR: a phase 3 study of alectinib versus chemotherapy in previously treated ALK plus non-small cell lung cancer (NSCLC)
Wolf, J.
Oh, I-J.
Mazieres, J.
de Castro, J.
Revil, C.
Kotb, A.
Johansdottir, H.
Zeaiter, A.
Novello, S.
ANNALS OF ONCOLOGY, 2016, 27
[8] INDIRECT TREATMENT COMPARISON OF ALECTINIB VS. BRIGATINIB IN ALK plus NON-SMALL CELL LUNG CANCER (NSCLC)
Wong, W.
Sheinson, D.
VALUE IN HEALTH, 2019, 22 : S59 - S59
[9] Adjuvant Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Preoperative Chemotherapy
Deng, L.
Jiang, C.
Perimbeti, S.
Chen, H.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S234 - S234
[10] ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB IIIA anaplastic lymphoma kinase-positive (ALK plus ) non-small cell lung cancer (NSCLC).
Solomon, Benjamin J.
Ahn, Jin Seok
Barlesi, Fabrice
Dziadziuszko, Rafal
Nishio, Makoto
Shaw, Alice Tsang
Bordogna, Walter
Meyenberg, Christoph
Wu, Yi-Long
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →